Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
Maria ChaparroIria Baston-ReyEstela Fernández-SalgadoJavier González GarcíaLaura RamosMaría Teresa Diz-Lois PalomaresFederico Argüelles-AriasEva Iglesias FloresMercedes CabelloSaioa Rubio IturriaAndrea Núñez OrtizMara CharroDaniel GinardCarmen Dueñas SadornilOlga Merino OchoaDavid BusquetsEduardo IyoAna GutiérrezPatricia Ramírez de la PiscinaMarta Maia Boscá-WattsMaite ArroyoMaría José GarcíaEsther HinojosaJordi GordilloPilar Martínez MontielBenito Velayos JiménezCristina Quílez IvorraJuan María Vázquez MorónJosé María HuguetYago González-LamaAna Isabel Muñagorri SantosVíctor Manuel AmoMaría Dolores Martín-ArranzFernando BermejoJesús Martínez CadillaCristina Rubín de CélixPaola Fradejas SalazarAntonio López San RománNuria JiménezSantiago García LópezAnna FiguerolaItxaso JiménezFrancisco José Martínez CerezoCarlos TaxoneraPilar VarelaRuth de FranciscoDavid MonfortGema Molina ArrieroAlejandro Hernández CambaFrancisco Javier García-AlonsoManuel Van DomselaarRamón Pajares VillarroyaAlejandro NúñezFrancisco Rodríguez MorantaIgnacio Marín-JiménezVirginia Robles AlonsoMaría Del Mar Martín RodríguezPatricia Camo-MonterdeIván García TerceroMercedes Navarro LlavatLara Arias GarcíaDaniel Hervías CruzSara SulleiroCynthia NovellaEugenia VispoManuel Barreiro-de AcostaJavier P GisbertPublished in: Inflammatory bowel diseases (2022)
Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice.